Back to top
more

AbbVie (ABBV)

(Delayed Data from NYSE)

$201.20 USD

201.20
7,194,067

-0.48 (-0.24%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $201.20 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks News

Ritujay Ghosh headshot

5 Solid Stocks to Watch That Recently Hiked Dividends

AbbVie Inc. (ABBV), Exxon Mobil Corporation (XOM), Kontoor Brands, Inc. (KTB), Select Water Solutions, Inc. (WTTR) and Macatawa Bank Corporation (MCBC) recently hiked dividends.

AbbVie (ABBV) Q3 Earnings Beat, Shares Down Despite Raised View

AbbVie's (ABBV) third-quarter 2023 earnings and sales beat estimates. Though the company raised its EPS outlook for both 2023 and 2024, share price dives as some key drugs misses out on estimates.

Compared to Estimates, AbbVie (ABBV) Q3 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for AbbVie (ABBV) give a sense of how the business performed in the quarter ended September 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

AbbVie (ABBV) Q3 Earnings and Revenues Beat Estimates

AbbVie (ABBV) delivered earnings and revenue surprises of 3.15% and 1.65%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Why Earnings Season Could Be Great for AbbVie (ABBV)

AbbVie (ABBV) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Why AbbVie (ABBV) is Poised to Beat Earnings Estimates Again

AbbVie (ABBV) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day

USA Compression and Disney have been highlighted as Zacks Bull and Bear of the Day.

Earnings Preview: Pfizer (PFE) Q3 Earnings Expected to Decline

Pfizer (PFE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

3 Biotech Stocks With Decent Dividend for a Steady Return

Here we pick three medical device stocks, AbbVie (ABBV), Amgen (AMGN) and Gilead Sciences (GILD), which have a solid five-year dividend growth history.

AbbVie (ABBV) Sees a More Significant Dip Than Broader Market: Some Facts to Know

In the latest trading session, AbbVie (ABBV) closed at $144.73, marking a -1.03% move from the previous day.

AbbVie (ABBV) to Report Q3 Earnings: What's in the Cards?

AbbVie's (ABBV) Q3 performance will likely reflect its newer immunotherapy drugs trying to compensate for declining Humira sales following the loss of U.S. exclusivity.

Earnings Preview: AbbVie (ABBV) Q3 Earnings Expected to Decline

AbbVie (ABBV) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific

Visa, AbbVie, BHP Group, Caterpillar and Boston Scientific are included in this Analyst Blog.

Sheraz Mian headshot

Top Research Reports for Visa, AbbVie & BHP

Today's Research Daily features new research reports on 16 major stocks, including Visa Inc. (V), AbbVie Inc. (ABBV) and BHP Group Limited (BHP).

Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?

Smart Beta ETF report for PJP

AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know

Zacks.com users have recently been watching AbbVie (ABBV) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now?

Smart Beta ETF report for NOBL

AbbVie (ABBV) Stock Sinks As Market Gains: Here's Why

AbbVie (ABBV) concluded the recent trading session at $147.23, signifying a -0.49% move from its prior day's close.

Eli Lilly's (LLY) Mirikizumab Meets Crohn's Disease Study Goals

Based on this data, Eli Lilly (LLY) will initiate regulatory submissions worldwide next year seeking regulatory approval for mirikizumab in Crohn's disease.

AbbVie's (ABBV) Rinvoq Meets Key Goal in Phase II Vitiligo Study

AbbVie (ABBV) meets the primary goal in the phase II study evaluating Rinvoq in the treatment of adult patients with non-segmental vitiligo.

Should iShares Core High Dividend ETF (HDV) Be on Your Investing Radar?

Style Box ETF report for HDV

AbbVie (ABBV) Rises Yet Lags Behind Market: Some Facts Worth Knowing

In the most recent trading session, AbbVie (ABBV) closed at $149.11, indicating a +0.59% shift from the previous trading day.

Kinjel Shah headshot

Pharma Stock Roundup: LLY Offers to Buy POINT Biopharma & Other Updates

Eli Lilly (LLY) offers to buy POINT Biopharma for approximately $1.4 billion. Sanofi (SNY) partners with Teva for co-developing immunology candidate.

AbbVie (ABBV) Buys Parkinson's Disease Treatment Maker

AbbVie's (ABBV) buyout of Mitokinin, which is making a novel treatment for Parkinson's Disease (PD), if successfully closed, is likely to strengthen its neuroscience pipeline.